Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Tovorafenib |
Trade Name | Ojemda |
Synonyms | BIIB-024|TAK-580|MLN-2480|TAK580|DAY101|MLN2480 |
Drug Descriptions |
Ojemda (tovorafenib) is an inhibitor of pan-Raf kinases, which interrupts RAF/MEK/ERK signal transduction pathways to inhibit tumor cell growth (PMID: 28082416, PMID: 30622172). Ojemda (tovorafenib) is FDA approved for use in patients 6 months or older with relapsed or refractory pediatric low grade glioma harboring BRAF fusion or rearrangement or BRAF V600 mutation (FDA.gov). |
DrugClasses | RAF Inhibitor (Pan) 28 |
CAS Registry Number | 1096708-71-2 |
NCIT ID | C106254 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Alisertib + Tovorafenib | Alisertib Tovorafenib | 0 | 1 |
Nivolumab + Tovorafenib | Nivolumab Tovorafenib | 0 | 2 |
Paclitaxel + Tovorafenib | Paclitaxel Tovorafenib | 0 | 1 |
Pimasertib + Tovorafenib | Pimasertib Tovorafenib | 0 | 1 |
Sapanisertib + Tovorafenib | Sapanisertib Tovorafenib | 0 | 1 |
Selumetinib + Tovorafenib | Selumetinib Tovorafenib | 0 | 0 |
Tovorafenib | Tovorafenib | 12 | 7 |
Tovorafenib + Vinblastine | Tovorafenib Vinblastine | 0 | 1 |